Chapter 1. Research Scope

1.1. Research Objectives

1.2. Market Definition

1.3. Analysis Period

1.4. Market Size Breakdown by Segments

1.4.1. Market size breakdown, by technology

1.4.2. Market size breakdown, by offering

1.4.3. Market size breakdown, by transplant type

1.4.4. Market size breakdown, by end user

1.4.5. Market size breakdown, by application

1.4.6. Market size breakdown, by region

1.4.7. Market size breakdown, by country

1.5. Market Data Reporting Unit

1.5.1. Value

1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.1.1. Paid

2.1.2. Unpaid

2.1.3. P&S Intelligence database

2.2. Primary Research

2.3. Market Size Estimation

2.4. Data Triangulation

2.5. Currency Conversion Rates

2.6. Assumptions for the Study

2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics

5.1.1. Trends

5.1.2. Drivers

5.1.3. Restraints/challenges

5.1.4. Impact analysis of drivers/restraints

5.2. Impact of COVID-19

5.3. Porter’s Five Forces Analysis

5.3.1. Bargaining power of buyers

5.3.2. Bargaining power of suppliers

5.3.3. Threat of new entrants

5.3.4. Intensity of rivalry

5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview

6.2. Market Revenue, by Technology (2017–2030)

6.2.1. Molecular assay market revenue, by type (2017–2030)

6.2.2. Non-molecular assay market revenue, by type (2017–2030)

6.3. Market Revenue, by Offering (2017–2030)

6.4. Market Revenue, by Transplant Type (2017–2030)

6.4.1. Solid organ market revenue, by type (2017–2030)

6.5. Market Revenue, by Application (2017–2030)

6.6. Market Revenue, by End User (2017–2030)

6.7. Market Revenue, by Region (2017–2030)

Chapter 7. North America Market

7.1. Overview

7.2. Market Revenue, by Technology (2017–2030)

7.2.1. Molecular assay market revenue, by type (2017–2030)

7.2.2. Non-molecular assay market revenue, by type (2017–2030)

7.3. Market Revenue, by Offering (2017–2030)

7.4. Market Revenue, by Transplant Type (2017–2030)

7.4.1. Solid organ market revenue, by type (2017–2030)

7.5. Market Revenue, by Application (2017–2030)

7.6. Market Revenue, by End User (2017–2030)

7.7. Market Revenue, by Country (2017–2030)

Chapter 8. Europe Market

8.1. Overview

8.2. Market Revenue, by Technology (2017–2030)

8.2.1. Molecular assay market revenue, by type (2017–2030)

8.2.2. Non-molecular assay market revenue, by type (2017–2030)

8.3. Market Revenue, by Offering (2017–2030)

8.4. Market Revenue, by Transplant Type (2017–2030)

8.4.1. Solid organ market revenue, by type (2017–2030)

8.5. Market Revenue, by Application (2017–2030)

8.6. Market Revenue, by End User (2017–2030)

8.7. Market Revenue, by Country (2017–2030)

Chapter 9. APAC Market

9.1. Overview

9.2. Market Revenue, by Technology (2017–2030)

9.2.1. Molecular assay market revenue, by type (2017–2030)

9.2.2. Non-molecular assay market revenue, by type (2017–2030)

9.3. Market Revenue, by Offering (2017–2030)

9.4. Market Revenue, by Transplant Type (2017–2030)

9.4.1. Solid organ market revenue, by type (2017–2030)

9.5. Market Revenue, by Application (2017–2030)

9.6. Market Revenue, by End User (2017–2030)

9.7. Market Revenue, by Country (2017–2030)

Chapter 10. LATAM Market

10.1. Overview

10.2. Market Revenue, by Technology (2017–2030)

10.2.1. Molecular assay market revenue, by type (2017–2030)

10.2.2. Non-molecular assay market revenue, by type (2017–2030)

10.3. Market Revenue, by Offering (2017–2030)

10.4. Market Revenue, by Transplant Type (2017–2030)

10.4.1. Solid organ market revenue, by type (2017–2030)

10.5. Market Revenue, by Application (2017–2030)

10.6. Market Revenue, by End User (2017–2030)

10.7. Market Revenue, by Country (2017–2030)

Chapter 11. MEA Market

11.1. Overview

11.2. Market Revenue, by Technology (2017–2030)

11.2.1. Molecular assay market revenue, by type (2017–2030)

11.2.2. Non-molecular assay market revenue, by type (2017–2030)

11.3. Market Revenue, by Offering (2017–2030)

11.4. Market Revenue, by Transplant Type (2017–2030)

11.4.1. Solid organ market revenue, by type (2017–2030)

11.5. Market Revenue, by Application (2017–2030)

11.6. Market Revenue, by End User (2017–2030)

11.7. Market Revenue, by Country (2017–2030)

Chapter 12. U.S. Market

12.1. Overview

12.2. Market Revenue, by Technology (2017–2030)

12.2.1. Molecular assay market revenue, by type (2017–2030)

12.2.2. Non-molecular assay market revenue, by type (2017–2030)

12.3. Market Revenue, by Offering (2017–2030)

12.4. Market Revenue, by Transplant Type (2017–2030)

12.4.1. Solid organ market revenue, by type (2017–2030)

12.5. Market Revenue, by Application (2017–2030)

12.6. Market Revenue, by End User (2017–2030)

Chapter 13. Canada Market

13.1. Overview

13.2. Market Revenue, by Technology (2017–2030)

13.2.1. Molecular assay market revenue, by type (2017–2030)

13.2.2. Non-molecular assay market revenue, by type (2017–2030)

13.3. Market Revenue, by Offering (2017–2030)

13.4. Market Revenue, by Transplant Type (2017–2030)

13.4.1. Solid organ market revenue, by type (2017–2030)

13.5. Market Revenue, by Application (2017–2030)

13.6. Market Revenue, by End User (2017–2030)

Chapter 14. Germany Market

14.1. Overview

14.2. Market Revenue, by Technology (2017–2030)

14.2.1. Molecular assay market revenue, by type (2017–2030)

14.2.2. Non-molecular assay market revenue, by type (2017–2030)

14.3. Market Revenue, by Offering (2017–2030)

14.4. Market Revenue, by Transplant Type (2017–2030)

14.4.1. Solid organ market revenue, by type (2017–2030)

14.5. Market Revenue, by Application (2017–2030)

14.6. Market Revenue, by End User (2017–2030)

Chapter 15. France Market

15.1. Overview

15.2. Market Revenue, by Technology (2017–2030)

15.2.1. Molecular assay market revenue, by type (2017–2030)

15.2.2. Non-molecular assay market revenue, by type (2017–2030)

15.3. Market Revenue, by Offering (2017–2030)

15.4. Market Revenue, by Transplant Type (2017–2030)

15.4.1. Solid organ market revenue, by type (2017–2030)

15.5. Market Revenue, by Application (2017–2030)

15.6. Market Revenue, by End User (2017–2030)

Chapter 16. U.K. Market

16.1. Overview

16.2. Market Revenue, by Technology (2017–2030)

16.2.1. Molecular assay market revenue, by type (2017–2030)

16.2.2. Non-molecular assay market revenue, by type (2017–2030)

16.3. Market Revenue, by Offering (2017–2030)

16.4. Market Revenue, by Transplant Type (2017–2030)

16.4.1. Solid organ market revenue, by type (2017–2030)

16.5. Market Revenue, by Application (2017–2030)

16.6. Market Revenue, by End User (2017–2030)

Chapter 17. Italy Market

17.1. Overview

17.2. Market Revenue, by Technology (2017–2030)

17.2.1. Molecular assay market revenue, by type (2017–2030)

17.2.2. Non-molecular assay market revenue, by type (2017–2030)

17.3. Market Revenue, by Offering (2017–2030)

17.4. Market Revenue, by Transplant Type (2017–2030)

17.4.1. Solid organ market revenue, by type (2017–2030)

17.5. Market Revenue, by Application (2017–2030)

17.6. Market Revenue, by End User (2017–2030)

Chapter 18. Spain Market

18.1. Overview

18.2. Market Revenue, by Technology (2017–2030)

18.2.1. Molecular assay market revenue, by type (2017–2030)

18.2.2. Non-molecular assay market revenue, by type (2017–2030)

18.3. Market Revenue, by Offering (2017–2030)

18.4. Market Revenue, by Transplant Type (2017–2030)

18.4.1. Solid organ market revenue, by type (2017–2030)

18.5. Market Revenue, by Application (2017–2030)

18.6. Market Revenue, by End User (2017–2030)

Chapter 19. Japan Market

19.1. Overview

19.2. Market Revenue, by Technology (2017–2030)

19.2.1. Molecular assay market revenue, by type (2017–2030)

19.2.2. Non-molecular assay market revenue, by type (2017–2030)

19.3. Market Revenue, by Offering (2017–2030)

19.4. Market Revenue, by Transplant Type (2017–2030)

19.4.1. Solid organ market revenue, by type (2017–2030)

19.5. Market Revenue, by Application (2017–2030)

19.6. Market Revenue, by End User (2017–2030)

Chapter 20. China Market

20.1. Overview

20.2. Market Revenue, by Technology (2017–2030)

20.2.1. Molecular assay market revenue, by type (2017–2030)

20.2.2. Non-molecular assay market revenue, by type (2017–2030)

20.3. Market Revenue, by Offering (2017–2030)

20.4. Market Revenue, by Transplant Type (2017–2030)

20.4.1. Solid organ market revenue, by type (2017–2030)

20.5. Market Revenue, by Application (2017–2030)

20.6. Market Revenue, by End User (2017–2030)

Chapter 21. India Market

21.1. Overview

21.2. Market Revenue, by Technology (2017–2030)

21.2.1. Molecular assay market revenue, by type (2017–2030)

21.2.2. Non-molecular assay market revenue, by type (2017–2030)

21.3. Market Revenue, by Offering (2017–2030)

21.4. Market Revenue, by Transplant Type (2017–2030)

21.4.1. Solid organ market revenue, by type (2017–2030)

21.5. Market Revenue, by Application (2017–2030)

21.6. Market Revenue, by End User (2017–2030)

Chapter 22. Australia Market

22.1. Overview

22.2. Market Revenue, by Technology (2017–2030)

22.2.1. Molecular assay market revenue, by type (2017–2030)

22.2.2. Non-molecular assay market revenue, by type (2017–2030)

22.3. Market Revenue, by Offering (2017–2030)

22.4. Market Revenue, by Transplant Type (2017–2030)

22.4.1. Solid organ market revenue, by type (2017–2030)

22.5. Market Revenue, by Application (2017–2030)

22.6. Market Revenue, by End User (2017–2030)

Chapter 23. South Korea Market

23.1. Overview

23.2. Market Revenue, by Technology (2017–2030)

23.2.1. Molecular assay market revenue, by type (2017–2030)

23.2.2. Non-molecular assay market revenue, by type (2017–2030)

23.3. Market Revenue, by Offering (2017–2030)

23.4. Market Revenue, by Transplant Type (2017–2030)

23.4.1. Solid organ market revenue, by type (2017–2030)

23.5. Market Revenue, by Application (2017–2030)

23.6. Market Revenue, by End User (2017–2030)

Chapter 24. Brazil Market

24.1. Overview

24.2. Market Revenue, by Technology (2017–2030)

24.2.1. Molecular assay market revenue, by type (2017–2030)

24.2.2. Non-molecular assay market revenue, by type (2017–2030)

24.3. Market Revenue, by Offering (2017–2030)

24.4. Market Revenue, by Transplant Type (2017–2030)

24.4.1. Solid organ market revenue, by type (2017–2030)

24.5. Market Revenue, by Application (2017–2030)

24.6. Market Revenue, by End User (2017–2030)

Chapter 25. Mexico Market

25.1. Overview

25.2. Market Revenue, by Technology (2017–2030)

25.2.1. Molecular assay market revenue, by type (2017–2030)

25.2.2. Non-molecular assay market revenue, by type (2017–2030)

25.3. Market Revenue, by Offering (2017–2030)

25.4. Market Revenue, by Transplant Type (2017–2030)

25.4.1. Solid organ market revenue, by type (2017–2030)

25.5. Market Revenue, by Application (2017–2030)

25.6. Market Revenue, by End User (2017–2030)

Chapter 26. Saudi Arabia Market

26.1. Overview

26.2. Market Revenue, by Technology (2017–2030)

26.2.1. Molecular assay market revenue, by type (2017–2030)

26.2.2. Non-molecular assay market revenue, by type (2017–2030)

26.3. Market Revenue, by Offering (2017–2030)

26.4. Market Revenue, by Transplant Type (2017–2030)

26.4.1. Solid organ market revenue, by type (2017–2030)

26.5. Market Revenue, by Application (2017–2030)

26.6. Market Revenue, by End User (2017–2030)

Chapter 27. South Africa Market

27.1. Overview

27.2. Market Revenue, by Technology (2017–2030)

27.2.1. Molecular assay market revenue, by type (2017–2030)

27.2.2. Non-molecular assay market revenue, by type (2017–2030)

27.3. Market Revenue, by Offering (2017–2030)

27.4. Market Revenue, by Transplant Type (2017–2030)

27.4.1. Solid organ market revenue, by type (2017–2030)

27.5. Market Revenue, by Application (2017–2030)

27.6. Market Revenue, by End User (2017–2030)

Chapter 28. U.A.E. Market

28.1. Overview

28.2. Market Revenue, by Technology (2017–2030)

28.2.1. Molecular assay market revenue, by type (2017–2030)

28.2.2. Non-molecular assay market revenue, by type (2017–2030)

28.3. Market Revenue, by Offering (2017–2030)

28.4. Market Revenue, by Transplant Type (2017–2030)

28.4.1. Solid organ market revenue, by type (2017–2030)

28.5. Market Revenue, by Application (2017–2030)

28.6. Market Revenue, by End User (2017–2030)

Chapter 29. Competitive Landscape

29.1. List of Market Players and their Offerings

29.2. Competitive Benchmarking of Key Players

29.3. Product Benchmarking of Key Players

29.4. Recent Strategic Developments

Chapter 30. Company Profiles

30.1. bioMérieux S.A.

30.1.1. Business overview

30.1.2. Product and service offerings

30.1.3. Key financial summary

30.2. Thermo Fisher Scientific Inc.

30.2.1. Business overview

30.2.2. Product and service offerings

30.2.3. Key financial summary

30.3. Bio-Rad Laboratories Inc.

30.3.1. Business overview

30.3.2. Product and service offerings

30.3.3. Key financial summary

30.4. Abbott Laboratories

30.4.1. Business overview

30.4.2. Product and service offerings

30.4.3. Key financial summary

30.5. Hologic Inc.

30.5.1. Business overview

30.5.2. Product and service offerings

30.5.3. Key financial summary

30.6. F. Hoffmann-La Roche Ltd.

30.6.1. Business overview

30.6.2. Product and service offerings

30.6.3. Key financial summary

30.7. Laboratory Corporation of America Holdings

30.7.1. Business overview

30.7.2. Product and service offerings

30.7.3. Key financial summary

30.8. BAG Diagnostics GmbH

30.8.1. Business overview

30.8.2. Product and service offerings

30.8.3. Key financial summary

30.9. Illumina Inc.

30.9.1. Business overview

30.9.2. Product and service offerings

30.9.3. Key financial summary

Chapter 31. Appendix

31.1. Abbreviations

31.2. Sources and References

31.3. Related Reports

※参考情報 移植診断は、臓器移植や細胞移植を行う際に、ドナーとレシピエントの適合性を評価し、移植の成功率を高めるために重要なプロセスです。これには、様々な定義や種類があり、医療現場で幅広く利用されています。 まず、移植診断の定義ですが、これは移植に際しての生体適合性の評価を指します。具体的には、ドナーから提供される臓器や組織が、受け取る患者の体にどの程度適合するかを判断することを意味しています。適合性が高いほど、拒絶反応が起こりにくく、移植後の合併症も少なくなります。 移植診断には主に二つの種類があります。一つは血液型適合性の検査です。ドナーとレシピエントのABO血液型が一致することは、移植の基本条件となります。次に、HLA型適合性の検査があります。HLA（ヒト白血球抗原）は、免疫系の自己と非自己を識別するための重要な要素であり、移植においてはHLAの一致が拒絶反応のリスクを大きく左右します。HLAタイプが一致するほど、移植後の生命予後は良好と言われています。 さらに、移植診断の用途は多岐にわたります。臓器移植においては、腎臓、肝臓、心臓、肺などあらゆる臓器に関与しています。特に、腎移植においては、ドナーとレシピエントのHLA型一致が非常に重要とされています。これにより、腎移植後の慢性拒絶反応を抑えることが可能になります。 最近では、移植診断の精度を向上させるために、関連技術も進化しています。例えば、次世代シーケンシング（NGS）技術があり、これはHLA型を非常に詳細に解析することが可能です。この技術により、多様なHLAの多型の検出が可能になり、より正確な適合性判定が実現されています。 また、抗体検査も重要な技術の一つです。移植前に行うこれらの抗体検査では、特定のHLAに対する感作の有無を確認することで、拒絶反応のリスクを予測できます。感作が見られる場合、移植後の拒絶反応のリスクが高まるため、慎重な評価が必要です。 さらに、移植診断には、臓器保存や輸送に関する技術も関与しています。臓器移植では、臓器を保存するための適切な温度管理や保存液の利用が欠かせません。これにより、ドナーからレシピエントへの移植時の臓器の状態を維持し、成功率を高めることができます。 最近では、人工臓器や再生医療の分野でも移植診断が重要な役割を果たしています。これらの分野では、移植が行われる際に、患者自身の細胞を用いることが多く、それに適した診断技術が求められています。特に、幹細胞技術を用いた治療法が注目されており、倫理的な問題や拒絶反応のリスクも考慮する必要があります。 最後に、移植診断は、臓器移植だけでなく、骨髄移植や幹細胞移植にも広く適用されています。これらの診断は、患者の健康状態や移植後の生活の質を高めるために不可欠なものです。移植医療は進化し続けており、それに伴い移植診断の重要性も増しています。今後、技術の進展とともに、より安全で成功率の高い移植が実現されることが期待されています。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer